Search

This document is a letter from J. Saunders in Warrenton, Virginia to D. Burford in Nashville, Tennessee. In the letter, Saunders mentions the conflict known as the "Bank War" between those associated with the second bank of the United States and president Andrew Jackson. Saunders also mentions their slave trade business.

This document is a letter dated December 8, 1832 from J. Saunders in Warrenton, Virginia to D. Burford in Dixons Springs, Tennessee. The subject of the letter is slave trade and transportation to the Mississippi area. In the letter, Saunders mentions that pestilence has had a major impact on the south and will be a factor in choosing a trade route.

This document is a letter from J. Saunders in Warrenton, Virginia to D. Burford in Nashville, Tennessee. In the letter, Saunders mentions the conflict known as the "Bank War" between those associated with the second bank of the United States and president Andrew Jackson. Saunders also mentions their slave trade business.

This document is a letter dated December 8, 1832 from J. Saunders in Warrenton, Virginia to D. Burford in Dixons Springs, Tennessee. The subject of the letter is slave trade and transportation to the Mississippi area. In the letter, Saunders mentions that pestilence has had a major impact on the south and will be a factor in choosing a trade route.

This document is a letter dated October 2, 1832 from J. Saunders in Warrenton, Virginia to David Burford in Dixons Spring, Tennessee. The subject of the letter is business, specifically slave labor speculation involving the purchase of slaves.

This document is a letter dated February 12, 1833 from J. Saunders in Warrenton, Virginia to David Burford. The subject of the letter is slave trade and demand.

This document is a letter dated January 23, 1835 from J. Saunders in Warrenton, Virginia to David Burford in Dixons Spring, Tennessee. The subject of the letter is business, specifically slave labor speculation involving the purchase of slaves to send to the market.

This document is a letter dated April 3, 1832 from J. Saunders in Warrenton, Virginia to David Burford in Dixons Spring, Tennessee. The subject of the letter is the business of slave labor speculation, including the purchase of slaves.

This document is a letter dated February 12, 1833 from J. Saunders in Warrenton, Virginia to David Burford. The subject of the letter is slave trade and demand.

This document is a letter dated October 2, 1832 from J. Saunders in Warrenton, Virginia to David Burford in Dixons Spring, Tennessee. The subject of the letter is business, specifically slave labor speculation involving the purchase of slaves.

This document is a letter dated January 23, 1835 from J. Saunders in Warrenton, Virginia to David Burford in Dixons Spring, Tennessee. The subject of the letter is business, specifically slave labor speculation involving the purchase of slaves to send to the market.

This document is a letter dated April 3, 1832 from J. Saunders in Warrenton, Virginia to David Burford in Dixons Spring, Tennessee. The subject of the letter is the business of slave labor speculation, including the purchase of slaves.

Deed of trust for the sale of a number of horses and a carriage.

INTRODUCTION: Detection of serum biomarkers for early diagnosis of breast cancer remains an important goal. Changes in the structure of O-linked glycans occur in all breast cancers resulting in the expression of glycoproteins that are antigenically distinct. Indeed the serum assay widely used for monitoring disease progression in breast cancer (CA15.3), detects a glycoprotein (MUC1), but elevated levels of the antigen cannot be detected in early stage patients. However, since the immune system acts to amplify the antigenic signal, antibodies can be detected in sera long before the antigen. We have exploited the change in O-glycosylation to measure autoantibody responses to cancer-associated glycoforms of MUC1 in sera from early stage breast cancer patients. METHODS: We used a microarray platform of 60mer MUC1 glycopeptides, to confirm the presence of autoantibodies to cancer associated glycoforms of MUC1 in a proportion of early breast cancer patients (54/198). Five positive sera were selected for detailed definition of the reactive epitopes using on chip glycosylation technology and a panel of glycopeptides based on a single MUC1 tandem repeat carrying specific glycans at specific sites. Based on these results, larger amounts of an extended repertoire of defined MUC1 glycopeptides were synthesised, printed on microarrays, and screened with sera from a large cohort of breast cancer patients (n=395), patients with benign breast disease (n=108) and healthy controls (n=99). All sera were collected in the 1970s and 80s and complete clinical follow up of breast cancer patients is available. RESULTS: The presence and level of autoantibodies was significantly higher in the sera from cancer patients compared with the controls, and a highly significant correlation with age was observed. High levels of a subset of autoantibodies to the core3MUC1 (GlcNAc1-3GalNAc-MUC1) and STnMUC1 (NeuAc2,6GalNAc-MUC1) glycoforms were significantly associated with reduced incidence a

INTRODUCTION: Detection of serum biomarkers for early diagnosis of breast cancer remains an important goal. Changes in the structure of O-linked glycans occur in all breast cancers resulting in the expression of glycoproteins that are antigenically distinct. Indeed the serum assay widely used for monitoring disease progression in breast cancer (CA15.3), detects a glycoprotein (MUC1), but elevated levels of the antigen cannot be detected in early stage patients. However, since the immune system acts to amplify the antigenic signal, antibodies can be detected in sera long before the antigen. We have exploited the change in O-glycosylation to measure autoantibody responses to cancer-associated glycoforms of MUC1 in sera from early stage breast cancer patients. METHODS: We used a microarray platform of 60mer MUC1 glycopeptides, to confirm the presence of autoantibodies to cancer associated glycoforms of MUC1 in a proportion of early breast cancer patients (54/198). Five positive sera were selected for detailed definition of the reactive epitopes using on chip glycosylation technology and a panel of glycopeptides based on a single MUC1 tandem repeat carrying specific glycans at specific sites. Based on these results, larger amounts of an extended repertoire of defined MUC1 glycopeptides were synthesised, printed on microarrays, and screened with sera from a large cohort of breast cancer patients (n=395), patients with benign breast disease (n=108) and healthy controls (n=99). All sera were collected in the 1970s and 80s and complete clinical follow up of breast cancer patients is available. RESULTS: The presence and level of autoantibodies was significantly higher in the sera from cancer patients compared with the controls, and a highly significant correlation with age was observed. High levels of a subset of autoantibodies to the core3MUC1 (GlcNAc1-3GalNAc-MUC1) and STnMUC1 (NeuAc2,6GalNAc-MUC1) glycoforms were significantly associated with reduced incidence a

INTRODUCTION: Detection of serum biomarkers for early diagnosis of breast cancer remains an important goal. Changes in the structure of O-linked glycans occur in all breast cancers resulting in the expression of glycoproteins that are antigenically distinct. Indeed the serum assay widely used for monitoring disease progression in breast cancer (CA15.3), detects a glycoprotein (MUC1), but elevated levels of the antigen cannot be detected in early stage patients. However, since the immune system acts to amplify the antigenic signal, antibodies can be detected in sera long before the antigen. We have exploited the change in O-glycosylation to measure autoantibody responses to cancer-associated glycoforms of MUC1 in sera from early stage breast cancer patients. METHODS: We used a microarray platform of 60mer MUC1 glycopeptides, to confirm the presence of autoantibodies to cancer associated glycoforms of MUC1 in a proportion of early breast cancer patients (54/198). Five positive sera were selected for detailed definition of the reactive epitopes using on chip glycosylation technology and a panel of glycopeptides based on a single MUC1 tandem repeat carrying specific glycans at specific sites. Based on these results, larger amounts of an extended repertoire of defined MUC1 glycopeptides were synthesised, printed on microarrays, and screened with sera from a large cohort of breast cancer patients (n=395), patients with benign breast disease (n=108) and healthy controls (n=99). All sera were collected in the 1970s and 80s and complete clinical follow up of breast cancer patients is available. RESULTS: The presence and level of autoantibodies was significantly higher in the sera from cancer patients compared with the controls, and a highly significant correlation with age was observed. High levels of a subset of autoantibodies to the core3MUC1 (GlcNAc1-3GalNAc-MUC1) and STnMUC1 (NeuAc2,6GalNAc-MUC1) glycoforms were significantly associated with reduced incidence a